<SEC-DOCUMENT>0001628280-25-039759.txt : 20250812
<SEC-HEADER>0001628280-25-039759.hdr.sgml : 20250812
<ACCEPTANCE-DATETIME>20250812070255
ACCESSION NUMBER:		0001628280-25-039759
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		14
CONFORMED PERIOD OF REPORT:	20250812
ITEM INFORMATION:		Results of Operations and Financial Condition
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20250812
DATE AS OF CHANGE:		20250812

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Adverum Biotechnologies, Inc.
		CENTRAL INDEX KEY:			0001501756
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		ORGANIZATION NAME:           	03 Life Sciences
		EIN:				205258327
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-36579
		FILM NUMBER:		251203993

	BUSINESS ADDRESS:	
		STREET 1:		100 CARDINAL WAY
		CITY:			REDWOOD CITY
		STATE:			CA
		ZIP:			94063
		BUSINESS PHONE:		(650) 649-1004

	MAIL ADDRESS:	
		STREET 1:		100 CARDINAL WAY
		CITY:			REDWOOD CITY
		STATE:			CA
		ZIP:			94063

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Avalanche Biotechnologies, Inc.
		DATE OF NAME CHANGE:	20100921
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>advm-20250812.htm
<DESCRIPTION>8-K
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2025 Workiva-->
<!--r:c3bcf673-8c64-4902-85d5-8e38d3d07f75,g:686b49fe-ab3e-49ac-b035-2e1fbdda8b68,d:6ef59548e4f94be39349d4ab9e0e5471-->
<html xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:dei="http://xbrl.sec.gov/dei/2025" xmlns="http://www.w3.org/1999/xhtml" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>advm-20250812</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="c-1" name="dei:AmendmentFlag" format="ixt:fixed-false" id="f-21">false</ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="dei:EntityCentralIndexKey" id="f-22">0001501756</ix:nonNumeric></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="advm-20250812.xsd"/></ix:references><ix:resources><xbrli:context id="c-1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501756</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2025-08-12</xbrli:startDate><xbrli:endDate>2025-08-12</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div><div id="i6ef59548e4f94be39349d4ab9e0e5471_1"></div><div style="min-height:54pt;width:100%"><div><span><br/></span></div></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"/></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:16pt;font-weight:700;line-height:120%">UNITED STATES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:16pt;font-weight:700;line-height:120%">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:120%">Washington</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">,</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:120%"> D.C. 20549</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:42.438%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"/></tr></table></div><div style="margin-bottom:9pt;margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:16pt;font-weight:700;line-height:120%">FORM <ix:nonNumeric contextRef="c-1" name="dei:DocumentType" id="f-1">8-K</ix:nonNumeric></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:42.438%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"/></tr></table></div><div><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">CURRENT REPORT</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">Pursuant to Section 13 or 15(d)</span></div><div style="margin-bottom:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">of the Securities Exchange Act of 1934</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en" id="f-2">August 12, 2025</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">Date of Report (Date of earliest event reported)</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:40.586%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:20pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityRegistrantName" id="f-3">Adverum Biotechnologies, Inc.</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">(Exact name of registrant as specified in its charter)</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:42.438%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"/></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.296%"><tr><td style="width:1.0%"/><td style="width:32.233%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:32.233%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:32.234%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen" id="f-4">Delaware</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityFileNumber" id="f-5">001-36579</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityTaxIdentificationNumber" id="f-6">20-5258327</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">(State or other jurisdiction<br/>of incorporation)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">(Commission<br/>File Number)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">(I.R.S. Employer<br/>Identification No.)</span></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityAddressAddressLine1" id="f-7">100 Cardinal Way</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityAddressCityOrTown" id="f-8">Redwood City</ix:nonNumeric>, <ix:nonNumeric contextRef="c-1" name="dei:EntityAddressStateOrProvince" id="f-9">CA</ix:nonNumeric> <ix:nonNumeric contextRef="c-1" name="dei:EntityAddressPostalZipCode" id="f-10">94063</ix:nonNumeric></span></div><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">(Address of principal executive offices, including zip code)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">(<ix:nonNumeric contextRef="c-1" name="dei:CityAreaCode" id="f-11">650</ix:nonNumeric>) <ix:nonNumeric contextRef="c-1" name="dei:LocalPhoneNumber" id="f-12">656-9323</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">(Registrant&#8217;s telephone number, including area code)</span></div><div style="text-align:center"><span><br/></span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">N/A</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">(Former name or former address, if changed since last report.)</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:42.438%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/></tr></table></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligations of the registrant under any of the following provisions:</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:WrittenCommunications" format="ixt:fixed-false" id="f-13">&#9744;</ix:nonNumeric>&#160;&#160;&#160;&#160;Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:SolicitingMaterial" format="ixt:fixed-false" id="f-14">&#9744;</ix:nonNumeric>&#160;&#160;&#160;&#160;Soliciting material pursuant to Rule 14a&#8211;12 under the Exchange Act (17 CFR 240.14a&#8211;12)</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:PreCommencementTenderOffer" format="ixt:fixed-false" id="f-15">&#9744;</ix:nonNumeric>&#160;&#160;&#160;&#160;Pre-commencement communications pursuant to Rule 14d&#8211;2(b) under the Exchange Act (17 CFR 240.14d&#8211;2(b))</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:PreCommencementIssuerTenderOffer" format="ixt:fixed-false" id="f-16">&#9744;</ix:nonNumeric>&#160;&#160;&#160;&#160;Pre-commencement communications pursuant to Rule 13e&#8211;4(c) under the Exchange Act (17 CFR 240.13e&#8211;4(c))</span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Securities registered pursuant to Section 12(b) of the Act:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:30.535%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.417%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:34.393%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.417%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:30.538%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Title of each class</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Trading<br/>Symbol(s)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Name of each exchange<br/>on which registered</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:Security12bTitle" id="f-17">Common Stock</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:TradingSymbol" id="f-18">ADVM</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="f-19">Nasdaq</ix:nonNumeric> Capital Market</span></div></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167; 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (&#167; 240.12b-2 of this chapter).</span></div><div style="margin-bottom:6pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Emerging growth company  <ix:nonNumeric contextRef="c-1" name="dei:EntityEmergingGrowthCompany" format="ixt:fixed-false" id="f-20">&#9744;</ix:nonNumeric></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  &#9744;</span></div><div style="margin-bottom:12pt"><span><br/></span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="i6ef59548e4f94be39349d4ab9e0e5471_7"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:120%">Item 2.02&#160;&#160;&#160;&#160;</span><span style="color:#212529;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:120%">Results of Operations and Financial Condition.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#212529;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">On </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en" id="f-23">August&#160;12, 2025</ix:nonNumeric></span><span style="color:#212529;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">, Adverum Biotechnologies, Inc. issued a press release announcing its financial results for the quarter ended June 30, 2025, and providing a corporate update. A copy of such press release is furnished herewith as Exhibit 99.1 and is incorporated herein by reference.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#212529;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">The information in this report, including the exhibit hereto, shall not be deemed &#8220;filed&#8221; for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section or Sections 11 and 12(a)(2) of the Securities Act of 1933, as amended. The information contained in this report and in the accompanying exhibit shall not be incorporated by reference into any filing with the U.S. Securities and Exchange Commission made by Adverum Biotechnologies, Inc., whether made before or after the date hereof, regardless of any general incorporation language in such filing.</span></div><div id="i6ef59548e4f94be39349d4ab9e0e5471_10"></div><div style="-sec-extract:summary;margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:120%">Item 9.01&#160;&#160;&#160;&#160;Financial Statements and Exhibits.</span></div><div style="margin-bottom:7pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:10.278%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:3.226%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:83.196%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:100%">Exhibit No.</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:100%">Description</span></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:100%">99.1</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline" href="exhibit991_81225pressrelea.htm">Press Release dated August 12, 2025, announcing Adverum Biotechnologies, Inc. financial results for the quarter ended June 30, 2025, and providing a corporate update.</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:100%">104</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:115%">The cover page of this report has been formatted in Inline XBRL.</span></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="i6ef59548e4f94be39349d4ab9e0e5471_13"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:120%">SIGNATURES</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</span></div><div style="margin-bottom:7pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.397%"><tr><td style="width:1.0%"/><td style="width:47.108%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.414%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:44.178%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:100%">Adverum Biotechnologies, Inc.</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:100%">Date: </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en" id="f-24">August&#160;12, 2025</ix:nonNumeric></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:100%">By:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:100%">/s/ Laurent Fischer</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:100%">Laurent Fischer, M.D. <br/>President and Chief Executive Officer</span></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>exhibit991_81225pressrelea.htm
<DESCRIPTION>EX-99.1
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2025 Workiva -->
<title>Document</title></head><body><div id="i9dc0d7a6e1b042bcb45e3104873a1851_1"></div><div style="min-height:58.5pt;width:100%"><div><font><br></font></div></div><div style="text-align:right;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Exhibit 99.1</font></div><div><img alt="logoa.jpg" src="logoa.jpg" style="height:58px;margin-bottom:5pt;vertical-align:text-bottom;width:182px"></div><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:115%">Adverum Biotechnologies Reports Second Quarter 2025 Financial Results and Provides Pipeline Highlights </font></div><div style="text-align:center"><font><br></font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;padding-right:18pt;text-align:center;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8211;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%;padding-left:12.53pt">ARTEMIS Phase 3 trial enrollment exceeding expectations&#59; driven by strong retina specialist and patient enthusiasm for a potential One And Done&#8482; therapy for wet AMD</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;padding-right:18pt;text-align:center;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8211;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%;padding-left:12.53pt">ARTEMIS enrollment completion expected in 1Q 2026, with topline data anticipated 1H 2027</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;padding-right:18pt;text-align:center;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8211;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%;padding-left:12.53pt">LUNA 2-year long-term follow-up data planned in 4Q 2025</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;padding-right:18pt;text-align:center;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8211;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%;padding-left:12.53pt">Announced $10 million private placement with Frazier Life Sciences</font></div><div><font><br></font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">REDWOOD CITY, Calif., August&#160;12, 2025 -- Adverum Biotechnologies, Inc. (Nasdaq&#58; ADVM), a clinical-stage company pioneering the use of gene therapy to preserve sight for life in highly prevalent ocular diseases, today reported financial results for the second quarter of 2025. The company also provided pipeline highlights and anticipated milestones.</font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'null',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">We are thrilled to report excellent progress in the ARTEMIS Phase 3 trial, with enrollment driven by robust interest from retina specialists and patients. We are well ahead of schedule, and momentum continues to build, with the number of screened and randomized patients surpassing our projections. This progress, along with increasing recognition of Ixo-vec&#8217;s potential as a best-in-class therapy, supports our active and ongoing partnering discussions. We are also excited about the recent vote of confidence from Frazier Life Sciences, one of our largest investors.</font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'null',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Additionally, a recent survey of nearly 1,000 retina specialists revealed that nearly 50% view gene therapy as the most exciting advancement in the wet AMD field&#8212;far surpassing TKIs.  Despite this enthusiasm, current market valuations continue to underappreciate gene therapy&#8217;s transformative potential, highlighting a real disconnect between clinical excitement and investor sentiment. This remarkable enthusiasm for ocular gene therapy, the only modality potentially addressing the unmet need for longer acting wet AMD treatment, and a potential One And Done</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">&#8482;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> therapy, underscores the unique potential for broad adoption and significant value inflection.</font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'null',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Later this year, we plan to present two-year follow-up data from LUNA.  We expect these long-term results will continue to build our growing dataset supporting the potential for Ixo-vec to offer lifelong, best-in-class therapy for wet AMD with a favorable long-term safety profile. We believe Ixo-vec, if approved, will provide retina specialists and their wet AMD patients with a compelling opportunity for a One And Done</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:7.15pt;font-weight:400;line-height:120%;position:relative;top:-3.85pt;vertical-align:baseline">TM</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> wet AMD treatment,</font><font style="color:#000000;font-family:'null',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> stated Laurent Fischer, M.D., president and chief executive officer of Adverum Biotechnologies.</font><font style="color:#000000;font-family:'null',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Ixo-vec Program Highlights</font></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8211;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:12.53pt">Driven by retina specialist and patient enthusiasm for a potential One And Done</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">&#8482;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> intravitreal gene therapy, site activation and enrollment in the ARTEMIS Phase 3 study have exceeded initial expectations.</font></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#9702;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.25pt">Enrollment in ARTEMIS is expected to be completed in the first quarter of 2026, with topline data expected in the first half of 2027.   </font></div><div style="height:58.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:58.5pt;width:100%"><div><font><br></font></div></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#9702;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.25pt">AQUARIUS, the second Phase 3 study, is anticipated to initiate in the fourth quarter of 2025, pending funding availability. </font></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8211;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:12.53pt">Long-term follow-up from the LUNA Phase 2 study continues, with two-year data expected to be presented in the fourth quarter of 2025. </font></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8211;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:12.53pt">As reported, the American Society of Retina Specialists recently voted gene therapy as the most exciting pipeline treatment for wet AMD. </font></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#9702;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.25pt">Of the almost 1,000 retina specialists surveyed, almost half selected gene therapy as the upcoming treatment they&#8217;re most enthusiastic about, more than the next three categories combined and, importantly, more than double the next category, tyrosine kinase inhibitors (TKIs).  This aligns with retina specialists&#8217; view that longer-duration therapies remain the largest unmet need in wet AMD.</font></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8211;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:12.53pt">In a separate survey conducted during the Clinical Trials at the Summit 2025 meeting, over half of 40 world-leading retina specialists identified gene therapies as the class of investigational treatments expected to offer the greatest patient benefit in ophthalmology, citing durability in managing wet AMD. By comparison, only about 18% selected TKIs.</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Private Placement with Frazier Life Sciences</font></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8211;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:12.53pt">Adverum announced that it has agreed to sell approximately $10 million of its common stock and pre-funded warrants in lieu thereof to Frazier Life Sciences in a private investment in public equity (&#34;PIPE&#34;) financing at a purchase price of $2.24 per share or $2.2399 per pre-funded warrant, representing the closing price on August 11, 2025. The pre-funded warrants will have an exercise price of $0.0001 per share of common stock.</font></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8211;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:12.53pt">The PIPE is expected to close on August 12, 2025, subject to customary closing conditions. There was no placement agent associated with this offering.  </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Upcoming Anticipated Milestones</font></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8211;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:12.53pt">4Q 2025&#160;&#160;&#160;&#160;Present Phase 2 LUNA two-year long-term follow-up data</font></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8211;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:12.53pt">4Q 2025&#160;&#160;&#160;&#160;Initiate AQUARIUS Phase 3 trial, pending funding availability</font></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8211;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:12.53pt">1Q 2026&#160;&#160;&#160;&#160;Complete enrollment in the ARTEMIS Phase 3 trial</font></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8211;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:12.53pt">1H 2027&#160;&#160;&#160;&#160;Announce topline data from the ARTEMIS Phase 3 trial</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Financial Results for the Three Months Ended June 30, 2025</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> </font></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:12.53pt">Cash, cash equivalents and short-term investments</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8239;were $44.4 million as of June 30, 2025, compared to $125.7 million as of December 31, 2024.  Adverum expects its cash, cash equivalents and short-term investments to fund operations into the fourth quarter of 2025. </font></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:12.53pt">Research and development expenses</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> were $37.1 million for the three months ended June 30, 2025, compared to $17.1 million for the same period in 2024. Research and development expenses increased due to higher clinical trial expenses and higher personnel related costs, both driven by the ARTEMIS Phase 3 clinical trial. Stock-based compensation expense included in research and development expenses was $1.1 million for the second quarter of 2025. </font></div><div style="height:58.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:58.5pt;width:100%"><div><font><br></font></div></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:12.53pt">General and administrative expenses</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8239;were $12.7 million for the three months ended June 30, 2025, compared to $15.8 million for the same period in 2024. General and administrative expenses were lower due to lower facilities expenses driven by sublease loss in prior year and lower personnel related costs driven by lower stock-based compensation expense. Stock-based compensation expense included in general and administrative expenses was $1.3 million for the second quarter of 2025. </font></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:12.53pt">Net loss</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> was $49.2 million, or $2.34 per basic and diluted share, for the three months ended June 30, 2025, compared to $30.5 million, or $1.46 per basic and diluted share for the same period in 2024. </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">About Ixo-vec in Wet AMD</font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Adverum is developing ixoberogene soroparvovec (Ixo-vec, formerly referred to as ADVM-022), its clinical-stage gene therapy product candidate, for the treatment of wet AMD. Ixo-vec utilizes a proprietary vector capsid, AAV.7m8, carrying an aflibercept coding sequence under the control of a proprietary expression cassette. Unlike other ophthalmic gene therapies that require surgery to administer the gene therapy under the retina (sub-retinal approach), Ixo-vec is designed to be administered as a one-time IVT injection in the physician&#8217;s office, deliver long-term efficacy, reduce the burden of frequent anti-VEGF, optimize patient compliance and improve vision outcomes for patients with wet AMD. In recognition of the need for new treatment options for wet AMD, FDA granted Fast Track and Regenerative Medicine Advanced Therapy (RMAT) designations for Ixo-vec for the treatment of wet AMD. Ixo-vec has also received PRIME designation from the EMA and the Innovation Passport from the United Kingdom&#8217;s Medicines and Healthcare Products Regulatory Agency for the treatment of wet AMD. </font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">About Adverum Biotechnologies</font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Adverum Biotechnologies (NASDAQ&#58; ADVM) is a clinical-stage company that aims to establish gene therapy as a new standard of care for highly prevalent ocular diseases with the aspiration of developing functional cures to restore vision and prevent blindness. Leveraging the capabilities of its proprietary intravitreal platform, Adverum is developing durable, single-administration therapies, designed to be delivered in physicians&#8217; offices, to eliminate the need for frequent ocular injections to treat these diseases. Adverum is evaluating its novel gene therapy candidate, ixoberogene soroparvovec (Ixo-vec, formerly referred to as ADVM-022), as a one-time, IVT injection for patients with neovascular or wet age-related macular degeneration. Additionally, by overcoming the challenges associated with current treatment paradigms for debilitating ocular diseases, Adverum aspires to transform the standard of care, preserve vision, and create a profound societal impact around the globe. For more information, please visit www.adverum.com.</font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Forward-looking Statements </font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Statements contained in this press release regarding events or results that may occur in the future are &#8220;forward-looking statements&#8221; within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements include but are not limited to statements regarding&#58;  the therapeutic and commercial potential of Ixo-vec, including its potential to be One-And-Done therapy for wet AMD patients&#59; increasing recognition of Ixo-vec&#8217;s potential as a best-in-class therapy&#59; gene therapy as the only modality potentially addressing the unmet need for longer acting wet AMD treatment&#59; plans and milestones related to Adverum&#8217;s product candidates, including the planned initiation of the global AQUARIUS Phase 3 trial&#59; presentation of LUNA Phase 2 two-year long-term follow-up data&#59; and completion of the enrollment and announcement of the topline data results from the ARTEMIS Phase 3 trial&#59; Adverum&#8217;s cash sufficiency and runway&#59; Adverum&#8217;s active and ongoing partnering discussions&#59; the unique potential for broad adoption and significant value inflection&#59; and other statements that are not a historical fact. Actual results could differ materially from those anticipated in such forward-looking statements as a </font></div><div style="height:58.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:58.5pt;width:100%"><div><font><br></font></div></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">result of various risks and uncertainties, including risks inherent to, without limitation&#58; Adverum&#8217;s novel technology, which makes it difficult to predict the timing of commencement and completion of clinical trials&#59; regulatory uncertainties&#59; enrollment uncertainties&#59; the results of early clinical trials not always being predictive of future clinical trials and results&#59; the potential for future complications or side effects in connection with use of Ixo-vec&#59; Adverum&#8217;s ability to continue as a going concern and improve its financial position&#59; and risks associated with market conditions. Additional risks and uncertainties facing Adverum are set forth under the caption &#8220;Risk Factors&#8221; and elsewhere in Adverum&#8217;s Securities and Exchange Commission (SEC) filings and reports, including Adverum&#8217;s most recent Annual Report on Form 10&#8209;K filed with the SEC on April 15, 2025 and subsequent filings with the SEC. All forward-looking statements contained in this press release speak only as of the date on which they were made. Adverum undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made, except as required by law. </font></div><div style="margin-top:18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Corporate &#38; Investor Inquiries&#58; </font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Adverum Investor Relations</font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Email&#58; </font><font style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">ir&#64;adverum.com</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">    </font></div><div style="margin-top:6pt"><font><br></font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Media&#58; </font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Jason Awe, Ph.D.</font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Executive Director, Corporate Communications</font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Email&#58; </font><font style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">jawe&#64;adverum.com</font></div><div style="height:58.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:58.5pt;width:100%"><div><font><br></font></div></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:53.907%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.063%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.235%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.111%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.084%"></td><td style="width:0.1%"></td></tr><tr><td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:112%">Adverum Biotechnologies, Inc.</font></div></td></tr><tr><td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">Selected Consolidated Balance Sheet Data</font></div></td></tr><tr><td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">(In thousands)</font></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:112%">June 30,</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:112%">December 31,</font></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:112%">2025</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:112%">2024</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">(Unaudited)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">(1)</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">Cash and cash equivalents, and marketable securities</font></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">44,397&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">125,691&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">Total assets</font></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">96,179&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">179,841&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">Total current liabilities</font></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">31,356&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">22,898&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">Total stockholders' (deficit) equity</font></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">(20,219)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">70,714&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:107%">(1) Derived from Adverum&#8217;s annual audited consolidated financial statements.</font></td></tr></table></div><div><font><br></font></div><div style="height:58.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:58.5pt;width:100%"><div><font><br></font></div></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:34.858%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.394%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.827%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.731%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.827%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.731%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.798%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.731%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.803%"></td><td style="width:0.1%"></td></tr><tr><td colspan="27" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:112%">Adverum Biotechnologies, Inc.</font></div></td></tr><tr><td colspan="27" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">Condensed Consolidated Statements of Operations</font></div></td></tr><tr><td colspan="27" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">(In thousands except per share data)</font></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:112%">Three months ended June 30,</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:112%">Six months ended June 30,</font></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:112%">2025</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:112%">2024</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:112%">2025</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:112%">2024</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(Unaudited)</font></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">Operating expenses&#58;</font></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">Research and development</font></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">37,125&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">17,097&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">65,872&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">32,507&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">General and administrative</font></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">12,730&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">15,807&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">32,204&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">29,596&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:24pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">Total operating expenses</font></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">49,855&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">32,904&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">98,076&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">62,103&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">Operating loss</font></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">(49,855)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">(32,904)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">(98,076)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">(62,103)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">Other income, net</font></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">664&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">2,406&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">1,866&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">4,458&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">Net loss</font></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">(49,191)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">(30,498)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">(96,210)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">(57,645)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">Net loss per share &#8212; basic and diluted</font></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">$</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">(2.34)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">$</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">(1.46)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">$</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">(4.59)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">$</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">(3.08)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">Weighted-average common shares outstanding - basic and diluted</font></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">21,010&#160;</font></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">20,852&#160;</font></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">20,974&#160;</font></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">18,713&#160;</font></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="27" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td></tr></table></div><div style="height:58.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>3
<FILENAME>advm-20250812.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2025 Workiva-->
<!--r:c3bcf673-8c64-4902-85d5-8e38d3d07f75,g:686b49fe-ab3e-49ac-b035-2e1fbdda8b68-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:advm="http://www.adverum.com/20250812" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.adverum.com/20250812">
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2025" schemaLocation="https://xbrl.sec.gov/dei/2025/dei-2025.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="advm-20250812_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="advm-20250812_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="Cover" roleURI="http://www.adverum.com/role/Cover">
        <link:definition>0000001 - Document - Cover</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>4
<FILENAME>advm-20250812_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2025 Workiva-->
<!--r:c3bcf673-8c64-4902-85d5-8e38d3d07f75,g:686b49fe-ab3e-49ac-b035-2e1fbdda8b68-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_dei_SolicitingMaterial_0925e1a8-c1b1-4ac8-be82-cb80b602b8b3_terseLabel_en-US" xlink:label="lab_dei_SolicitingMaterial" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Soliciting Material</link:label>
    <link:label id="lab_dei_SolicitingMaterial_label_en-US" xlink:label="lab_dei_SolicitingMaterial" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Soliciting Material</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SolicitingMaterial" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SolicitingMaterial"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SolicitingMaterial" xlink:to="lab_dei_SolicitingMaterial" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_WrittenCommunications_b0d41036-6fb5-4ace-a452-b0b3f7e9c703_terseLabel_en-US" xlink:label="lab_dei_WrittenCommunications" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Written Communications</link:label>
    <link:label id="lab_dei_WrittenCommunications_label_en-US" xlink:label="lab_dei_WrittenCommunications" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Written Communications</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_WrittenCommunications" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_WrittenCommunications"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_WrittenCommunications" xlink:to="lab_dei_WrittenCommunications" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_5176734a-b2df-4706-9d2b-9daae6b5f052_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_27db897b-1e56-4294-b11b-529dd478838d_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_PreCommencementTenderOffer_2301542c-61f7-4f5b-a06d-7b72cafa46f7_terseLabel_en-US" xlink:label="lab_dei_PreCommencementTenderOffer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
    <link:label id="lab_dei_PreCommencementTenderOffer_label_en-US" xlink:label="lab_dei_PreCommencementTenderOffer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementTenderOffer" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_PreCommencementTenderOffer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_PreCommencementTenderOffer" xlink:to="lab_dei_PreCommencementTenderOffer" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_0e8bdfcb-4aa9-491f-9e3f-1be4035e0639_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCentralIndexKey_2f5d24d7-0276-436a-a875-e5cfc388e8ec_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_PreCommencementIssuerTenderOffer_5986f458-90da-4a11-be94-5a0b36b02210_terseLabel_en-US" xlink:label="lab_dei_PreCommencementIssuerTenderOffer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
    <link:label id="lab_dei_PreCommencementIssuerTenderOffer_label_en-US" xlink:label="lab_dei_PreCommencementIssuerTenderOffer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementIssuerTenderOffer" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_PreCommencementIssuerTenderOffer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_PreCommencementIssuerTenderOffer" xlink:to="lab_dei_PreCommencementIssuerTenderOffer" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_569d1ed0-f5ee-4654-9621-eae4a3ce6a45_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_5c1494de-c955-4782-918f-7cc2d72f2bd0_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_dc095c01-e89f-48ad-ae6b-c60652d55730_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_302b07ea-5710-4387-91bb-07c6bd61e501_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SecurityExchangeName_00806b1d-13d9-4d4c-a264-2ed3fdbd91da_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SecurityExchangeName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_cf6ae07a-187e-4a26-94a4-c70315ebd9b6_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_0d76f1a3-80d6-4a69-b56f-5da0930158c1_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_01332c8c-9d74-453c-b4d0-a222874208a6_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressStateOrProvince_dd035171-dca2-4fa1-a613-e683c152ca11_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressStateOrProvince"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_fdd8fe1a-fe30-4310-8b8b-f0c5de3e6e5e_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_150400ab-f6b9-4f2f-842e-4428b18064ce_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_65087c8c-7356-4970-8fee-065dd2b1012b_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_e5563030-e40f-4ff9-814d-dfaace71ba34_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_87340280-cd64-4ba0-b13e-18cf5e1224d6_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>5
<FILENAME>advm-20250812_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2025 Workiva-->
<!--r:c3bcf673-8c64-4902-85d5-8e38d3d07f75,g:686b49fe-ab3e-49ac-b035-2e1fbdda8b68-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.adverum.com/role/Cover" xlink:type="simple" xlink:href="advm-20250812.xsd#Cover"/>
  <link:presentationLink xlink:role="http://www.adverum.com/role/Cover" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_7349a163-ab50-451c-a04f-e6023192f47c" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_74859cb7-12c2-4019-b56f-fe24262ebb72" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_7349a163-ab50-451c-a04f-e6023192f47c" xlink:to="loc_dei_DocumentType_74859cb7-12c2-4019-b56f-fe24262ebb72" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_4c8e19d2-9fd5-4dcb-9399-d5032f58453e" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_7349a163-ab50-451c-a04f-e6023192f47c" xlink:to="loc_dei_DocumentPeriodEndDate_4c8e19d2-9fd5-4dcb-9399-d5032f58453e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_3873debb-e2c7-4f46-953f-f9f3ac55b677" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_7349a163-ab50-451c-a04f-e6023192f47c" xlink:to="loc_dei_EntityRegistrantName_3873debb-e2c7-4f46-953f-f9f3ac55b677" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_2736783f-c64a-486a-a78d-f427c88c4d3c" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_7349a163-ab50-451c-a04f-e6023192f47c" xlink:to="loc_dei_EntityIncorporationStateCountryCode_2736783f-c64a-486a-a78d-f427c88c4d3c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_457cdd58-3f7e-40cb-be42-70ed0f59585a" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_7349a163-ab50-451c-a04f-e6023192f47c" xlink:to="loc_dei_EntityFileNumber_457cdd58-3f7e-40cb-be42-70ed0f59585a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_392aaa51-4a61-43a4-9c7b-11ec09240f88" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_7349a163-ab50-451c-a04f-e6023192f47c" xlink:to="loc_dei_EntityTaxIdentificationNumber_392aaa51-4a61-43a4-9c7b-11ec09240f88" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_3aba235c-8394-49f1-9773-05a518a10725" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_7349a163-ab50-451c-a04f-e6023192f47c" xlink:to="loc_dei_EntityAddressAddressLine1_3aba235c-8394-49f1-9773-05a518a10725" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_770883ac-3c36-4d56-b138-be753604b889" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_7349a163-ab50-451c-a04f-e6023192f47c" xlink:to="loc_dei_EntityAddressCityOrTown_770883ac-3c36-4d56-b138-be753604b889" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_6e6f1e3a-8ae8-46f3-8d30-8324d40f5834" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressStateOrProvince"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_7349a163-ab50-451c-a04f-e6023192f47c" xlink:to="loc_dei_EntityAddressStateOrProvince_6e6f1e3a-8ae8-46f3-8d30-8324d40f5834" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_3b3a24d9-8fc3-451d-8560-c2ba719b77c8" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_7349a163-ab50-451c-a04f-e6023192f47c" xlink:to="loc_dei_EntityAddressPostalZipCode_3b3a24d9-8fc3-451d-8560-c2ba719b77c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_8b42bfb5-3232-4bb4-9b1a-b896b512505d" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_7349a163-ab50-451c-a04f-e6023192f47c" xlink:to="loc_dei_CityAreaCode_8b42bfb5-3232-4bb4-9b1a-b896b512505d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_b4a0716e-fe16-487c-9e73-c91651ff4c79" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_7349a163-ab50-451c-a04f-e6023192f47c" xlink:to="loc_dei_LocalPhoneNumber_b4a0716e-fe16-487c-9e73-c91651ff4c79" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_WrittenCommunications_05427977-eecd-4899-acbb-e86077706311" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_WrittenCommunications"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_7349a163-ab50-451c-a04f-e6023192f47c" xlink:to="loc_dei_WrittenCommunications_05427977-eecd-4899-acbb-e86077706311" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SolicitingMaterial_837ee6a2-b493-4559-8612-fe5a60a1e935" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SolicitingMaterial"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_7349a163-ab50-451c-a04f-e6023192f47c" xlink:to="loc_dei_SolicitingMaterial_837ee6a2-b493-4559-8612-fe5a60a1e935" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementTenderOffer_956ea14d-14c3-4cbc-8c25-16b6a410cee0" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_PreCommencementTenderOffer"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_7349a163-ab50-451c-a04f-e6023192f47c" xlink:to="loc_dei_PreCommencementTenderOffer_956ea14d-14c3-4cbc-8c25-16b6a410cee0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementIssuerTenderOffer_052f0165-2fa7-4d64-acb2-c14f0abf6b91" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_PreCommencementIssuerTenderOffer"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_7349a163-ab50-451c-a04f-e6023192f47c" xlink:to="loc_dei_PreCommencementIssuerTenderOffer_052f0165-2fa7-4d64-acb2-c14f0abf6b91" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_339e96c4-e707-4280-9622-498f10433de9" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_7349a163-ab50-451c-a04f-e6023192f47c" xlink:to="loc_dei_Security12bTitle_339e96c4-e707-4280-9622-498f10433de9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_00992502-3fc1-4cd4-abad-6d9ddc818c47" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_7349a163-ab50-451c-a04f-e6023192f47c" xlink:to="loc_dei_TradingSymbol_00992502-3fc1-4cd4-abad-6d9ddc818c47" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_d4572d14-3139-4fa7-bce4-421e5f80e493" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SecurityExchangeName"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_7349a163-ab50-451c-a04f-e6023192f47c" xlink:to="loc_dei_SecurityExchangeName_d4572d14-3139-4fa7-bce4-421e5f80e493" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_8c73a985-a970-420f-929a-8204b8214872" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_7349a163-ab50-451c-a04f-e6023192f47c" xlink:to="loc_dei_EntityEmergingGrowthCompany_8c73a985-a970-420f-929a-8204b8214872" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_86d4c887-7a4f-4172-9df6-55c4db9ca37c" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_7349a163-ab50-451c-a04f-e6023192f47c" xlink:to="loc_dei_EntityCentralIndexKey_86d4c887-7a4f-4172-9df6-55c4db9ca37c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_2a7950c4-d3ab-4987-8a65-99137c2ffa2b" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_7349a163-ab50-451c-a04f-e6023192f47c" xlink:to="loc_dei_AmendmentFlag_2a7950c4-d3ab-4987-8a65-99137c2ffa2b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>6
<FILENAME>logoa.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 logoa.jpg
M_]C_X  02D9)1@ ! 0$ W #<  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" "? ?$# 2(  A$! Q$!_\0
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **3-+0 4444 %%%)F@!:*3-&: %HHHH ***3- "T4E+0 4444 %%%)0 M%)
MFEH **3-+0 4444 %%)FC(H 6BDI: "BBDR* %HHHH **2EH ***2@!:***
M"BBDH 6BBB@ HHHH ***2@!:*** "BBB@ HHHH **** "BBB@ HHHH ****
M"DI:2@!M<+\5/BYHGPCT:*_U<R2&9_+B@A&7<_2NXD8*I). !DU^?/[3'CRX
M^)WQ2DT_3O,NK33R;6VBB^;>X^\P]3GC\*WI4_:/78\#.,Q>7X?FA\3V/N7P
M%XZTSXC>&[;6])D9[6;^%AAD(ZJ:Z3-?$_[&/Q(;0?$UWX1OI/+M[TF2W5OX
M91]Y?QK[7&:FI#D=C?*L<LPPRJOXNOJ/I*6D[5D>P075Q'9V\DTSB.*-2[,W
M0 <DFO"[K]LSX?VMU+"'OYO+<KYD=O\ *V.XYKW*^M(M0LYK:==\,R&-U/=2
M,$5\WW7[#OA*XNY7@UG4H8V<LL*LA"#T'%7"5).U1GBYB\P2C]22?>YM?\-J
M> /34?\ P''^-26_[9WP^F<*SW\0/\36_'X\US__  PIX8_Z#NJ?^.?X56OO
MV$=":$_9/$6H1RXX,JHR_P JZ?W)X7M,_6O+$]H\(_&SP9XV=$TO7;:2=ND,
MC;'^F#UKNE(9<@YKX!^(7[)OC+P#&^HZ8RZW:0_,9+0%)D'7.WO^%:GP/_:J
MU?P7?0:/XJFEU'12WE^?+DS6W./J0/0\BE*BFKP9I0SVI1J*CF%/D;Z]#[JK
MRCXG?M&^%OA9X@MM&U/[1/>RJ'D$"9$*GH6^M>FZ?J%OJME!=VDR3VTZ"2.2
M,Y5E(R#7R)^W#\/FAU#2_&%M&3'*!971 Z$?<8_J/PK*G%2E:1[&;8JMAL(Z
M^'U:_(^M]'U:UUW3+;4+&59[2YC$L<B]&4\@U>7.:^<?V+?B%_;W@BX\.7,F
MZZTE_P!WD\F%NGY'-?1XYJ)QY)-'9@<4L9AXUEU'4AI::U0=YRGQ&^(VD?"_
MPW+K6LR,ENK!$CC&7D8]% ]:S_A1\7=$^+^CSW^CF5#;OY<T$PPZ,1D?F.]?
M*_[:GQ"_MSQE:>'()<VFDIYDP!X\YO\  5[A^R+\/6\%_"^&^N4:._UE_M<B
MMU"8P@_+^==+IJ--29\M1S.KB<SEAJ6L([^IZMXR\8:7X#\/W6LZO/\ 9[&W
M7+-C))/0 >IKQX?MI> ..-2_\!Q_C5G]LK_DBE[_ -?,/_H5?-O[-_P-TKXS
M2:TFI7MU9_8@A3[,1SNSUR*J%.#AS2.7,\QQM/&QPF#2NUU/HG_AM+P!Z:E_
MX#C_ .*H_P"&U/  [:E_X#C_ .*K%_X86\*_]!O5/S3_  I?^&%?"O\ T&]4
M_-/\*?[DGGS_ /EB;/\ PVI\/^F-2_\  <?_ !5=[\+_ (W>&OBVUVFARS>?
M:X,D,Z;'VGHP]J\H_P"&%?"N?^0UJGYI_A7I'P?^ 6@_!J2^GTR>YN[J[ 22
M>Y()"C^$ =JSDJ5O=W.W!RSAUE]94>7K8]-Z<"O)O'W[3/@WX=>()=&U">XF
MOH5!E2VCWA,] 3GK7K5?FU^T%'YWQU\41DX#7RKGV*J*5&"F]33/<PK9?1C.
M@E=NQ]4K^VGX ]-1_P# <?XT?\-I^ /34O\ P''^-<UIO[#_ (9OM/M;@ZYJ
M:F:)9"!LZD ^E6?^&%?#'_0>U/\ \<_PK6U'N>7&IG\E=1B=/I_[8WP\OIQ&
M]S=VF3C?/!A1^1->J^%_&VA>,[,7&B:G;ZA%W\EP2/J.H_*OFKQ!^PE:_9V;
M1O$=PLX'"7<:LI/U&,5X#J6F^,_V>?&L:F233=0B.^.2-B8;A,_J#Z&CV=.?
MPO4SEFV99>T\=2]U]4?IC5>^O(M/LYKJ=Q'!"AD=CV4#)-<5\&?B9;_%;P+9
MZU$HBN/]5<PY^Y*/O#Z=ZV?B,=O@'Q!_UXS?^@&N7EM+E9]BL1&I0]O3=U:Z
M.)^''[27A7XF^*)]#TQKB.Z4,T33( LRKU*UZTO2OSM_9%_Y+7HO_7"7_P!
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M\;8S@CZ5\1_M2?$;_A/OB==0P2[]-TH&T@QT+ _.P^IX_ 5[5^P?QX7\3?\
M7['_ .@&NMT5&GS'QF&SN>)S1X6-N17_  /J44ZFX/>G5R'V@M%%% !1110
M4444 %%%% !1110 4444 %(W2BD9AB@#RW]HKXD+\-_AM?W43A=0NE^S6JYP
M=[<9'T'-?.G[&OPU;Q)XIO/%6H1F2VL<I"SCAYFZG\ :Q/VJ/'D_Q(^*<7A[
M3"T]KITGV2)$Y#W#'#'\#Q^!K["^$'@&'X;^ =+T:-1YT<8>=A_%(1EC^?\
M*NQ_NJ?FSX6"_M;-')ZTZ7YGQ?\ M >#[OX._&)-6TU6AMKB87]JR\ ,#EE_
MSZU]O_#?QE;>/O!NF:W;,K)<PJ7 _A?^(?G7 _M1_#<>/_AO=301[M2TP&Y@
MXY( ^9?R_E7SA^SK^T9;?"/0=7TK68;F[M]WG6<4(!(?^)3GH.]-Q]M336YG
M3JPR3,9PJ.U.>J/O,XVYS7!>/OC=X.^&ZD:SK$0NNUG#^\F/_ 1T_'%?(/CC
M]JCQW\2KPZ9H,<FD6\QVI:Z<IDN7![%ASGZ8K0^'O['WBWQI*FH>)KDZ%:R'
M<RRGS;J3/MG"_B<^U2J*CK-G94SVKB9>RRZFY/N]CZIOOB!!XP^%EUXB\*SM
M<))$WELJD.A!PP([$<UX]\+=?UEO&UBD-S<7 F?$Z,Q8%>Y->[^ _ FC_"WP
M?%HNG;DTZV#.\EPP+,3RS,:YSX<?%;X?>-/$=_IWAF: ZE%EGVVYC\T X+*2
M!N&:^ SCA_$9EF%'&4*[C&GNNY^@8#-J>$PKPV*@O:3_ #/3AFGTVES[5]GJ
M<(C@,", CN*^//VP/@=;:7 ?&VB6XA1G":A!&N%YZ2#\>#7V'7,_$S18?$'@
M#7["<;HYK*48]PI(_4"MJ<W&2/'S3!PQN&E"2U6Q\\?L2_$^;4+.^\&WTID:
MS7[39%SSY1.&0>P//T-?0'Q4\$P?$/P'J^B3*";B%O*8C[L@Y4_F*^#_ -F+
M4I-'^./AP1L5\^22UD]P5)_FHK]'/O#FM:RY)W1X^0U7C<O=&KK:Z/S@^!'C
M"X^%/Q=L_MI:"(S&PO4;@#)QD_0X-?H]'(LJAT.58 @BO@S]L+X>_P#"(_$=
M=;M$,=EK"^:64<+,/O?GUKZC_9N^((^(/POTVXD???6B_9;CGG<HP#^(Q55E
MS)5$<N0U)83$5<NJ='='J58?C;Q-;^#?"NIZU=,%BLX&DY[D#@?B<5N-TKY9
M_;=^(/\ 9^AZ=X3MI,2WK?:+D*?^6:_=!^IK"G'FDD?39EBE@\+.L^BT]3YX
M^'^@7OQL^,5M#=%I#J%XUW=N><1 [F_H*_2>SM8[.UBMX5"11($11V & *^8
MOV(_AW_9_A^_\6W46)M0;R+8L.1$IY/XFOJ,9YK2O+WK+H>-P[A'1PSKU/BG
MK\CPW]LL?\65NS_T]0_^A5YK^P:?])\5_P"[%_,UZ3^V7_R1.\_Z^H?_ $*O
MFS]G/XY:7\%Y-9;4;"ZO?MH0(+7;\NW/7)%:P3E1:1Y>/KT\-G=.K5=DD?H-
M17S-_P -V>%_^@#JO_D/_P"*H_X;L\+_ /0 U7_R'_\ %5S^QJ=CZ/\ MS+_
M /GZCZ9I:^95_;J\*LZ[]#U5(\_,V$.T=SC=7T1X?UNU\3:+9ZI8R>;:7<2R
MQMT)!&:B5.4/B.["X_#8QM4)WL:7\-?FU\?O^2]^)/\ L()_):_27^&OS:^/
MO_)>_$O_ &$$_DM=&&^)GS7%/\"E_B/T4\/_ /(!T_\ Z]X__016C65X?N(O
M[!T\>8H_T>//(_NBM#[5%_SU3_OJN9I\ST/K:4X^SCKT)<U\X?MN:+:77PWL
MM2D1?M=K=JL38^8AA@BO=M<\6:-X;M&NM4U.UL;=1DR3RA1^IYKXB_:@^/=K
M\4KZVT;0R[Z)92;S.5P;B7H"H]!V]:VHQES)GS^?8NA#!SIR:<GHD>A_L&WD
MS:?XLM228$GA=?3<5.?Z5](?$;_D0?$/_7C-_P"@&O,/V2OAK=> ?AR;K48F
M@U'5I!<O&PP43&$!]\?SKT[XC?\ (@^(?^O&;_T T5&G4N7EU*='*E"IORO\
MCX2_9%_Y+7HG_7"7_P! -?HE7YW?LB_\ELT3_KA+_P"@&OT1JL1\2.'A;_=)
M?XF+1117*?9G@/[:7_)'V_Z_(_ZUPG[!?^I\6?[\'\FKN_VTO^2/M_U^1_UK
MA/V"S^Y\6?[\'\FKLC_!9\+B/^1_3]#ZQO/^/.?_ '&_E7Y;-H=QXD\>7NF6
M@!N;B^G6,'G)WMQ7ZDWW_'G/_N'^5?G#\*QN_:#TH8'.M..?^NC4\.[)LSXH
MIJM.A3;W9V?[(/Q";P;\1)= O6,-IJF8=K'A)U/']17WAVK\]?VDO!4_PO\
MBX^I6"M!;7KB_M77@+)G+ ?CS^-?;/PF\<0_$/P'I6MQ,&>:("8?W9!PP^N?
MYU-:*=IHZ.'ZTJ,JF7U=X/3T.RZUYM\?_B(GPW^&NJ:@CA;V9?L]JN>3(PQG
M\!S^%>D# 6OA3]LCXBMXI\=Q>'K1]]II(VLJG(>9L9_+@5E2AS2/8SK&?4\)
M*4?B>B^9X='H=Y?:'?:XP)M8+A('D;JTCY.!^ .:^M_V#L_\(SXF_P"OR/\
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MQ9N;/<?X3]]?P//XU]:"N*K>,K,^[RBM2Q&$A.G&W1^IB>.O^1,US_KRF_\
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M'B:68T^CLS]$[JYCL[>6>5@D<:EV)Z  9S7YO^/M6O?CA\:IEM"TGV^[%I;
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ I*6B@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
,* "BBB@ HHHH __9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>8
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Cover<br></strong></div></th>
<th class="th"><div>Aug. 12, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Aug. 12,  2025<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Adverum Biotechnologies, Inc.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-36579<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">20-5258327<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">100 Cardinal Way<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Redwood City<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">CA<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">94063<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">650<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">656-9323<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">ADVM<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001501756<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14a<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>9
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>10
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
.report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

.report table.authRefData a {
	display: block;
	font-weight: bold;
}

.report table.authRefData p {
	margin-top: 0px;
}

.report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

.report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

.report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

.report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
.pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
.report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

.report hr {
	border: 1px solid #acf;
}

/* Top labels */
.report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

.report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

.report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

.report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

.report td.pl div.a {
	width: 200px;
}

.report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
.report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
.report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
.report .re, .report .reu {
	background-color: #def;
}

.report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
.report .ro, .report .rou {
	background-color: white;
}

.report .rou td {
	border-bottom: 1px solid black;
}

.report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
.report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
.report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

.report .nump {
	padding-left: 2em;
}

.report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
.report .text {
	text-align: left;
	white-space: normal;
}

.report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

.report .text .more {
	display: none;
}

.report .text .note {
	font-style: italic;
	font-weight: bold;
}

.report .text .small {
	width: 10em;
}

.report sup {
	font-style: italic;
}

.report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.25.2</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>22</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>0</UnitCount>
  <MyReports>
    <Report instance="advm-20250812.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0000001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adverum.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="8-K" isOnlyDei="true" original="advm-20250812.htm">advm-20250812.htm</File>
    <File>advm-20250812.xsd</File>
    <File>advm-20250812_lab.xml</File>
    <File>advm-20250812_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="24">http://xbrl.sec.gov/dei/2025</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>14
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "advm-20250812.htm": {
   "nsprefix": "advm",
   "nsuri": "http://www.adverum.com/20250812",
   "dts": {
    "inline": {
     "local": [
      "advm-20250812.htm"
     ]
    },
    "schema": {
     "local": [
      "advm-20250812.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "https://www.xbrl.org/dtr/type/2024-01-31/types.xsd",
      "https://xbrl.sec.gov/dei/2025/dei-2025.xsd"
     ]
    },
    "labelLink": {
     "local": [
      "advm-20250812_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "advm-20250812_pre.xml"
     ]
    }
   },
   "keyStandard": 22,
   "keyCustom": 0,
   "axisStandard": 0,
   "axisCustom": 0,
   "memberStandard": 0,
   "memberCustom": 0,
   "hidden": {
    "total": 2,
    "http://xbrl.sec.gov/dei/2025": 2
   },
   "contextCount": 1,
   "entityCount": 1,
   "segmentCount": 0,
   "elementCount": 23,
   "unitCount": 0,
   "baseTaxonomies": {
    "http://xbrl.sec.gov/dei/2025": 24
   },
   "report": {
    "R1": {
     "role": "http://www.adverum.com/role/Cover",
     "longName": "0000001 - Document - Cover",
     "shortName": "Cover",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "advm-20250812.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "advm-20250812.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://www.adverum.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amendment Flag",
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "CityAreaCode",
     "presentation": [
      "http://www.adverum.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "City Area Code",
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://www.adverum.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Period End Date",
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentType",
     "presentation": [
      "http://www.adverum.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Type",
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://www.adverum.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, Address Line One",
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://www.adverum.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, City or Town",
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://www.adverum.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, Postal Zip Code",
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://www.adverum.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, State or Province",
        "label": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://www.adverum.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Central Index Key",
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://www.adverum.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Emerging Growth Company",
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://www.adverum.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity File Number",
        "label": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://www.adverum.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Incorporation, State or Country Code",
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://www.adverum.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Registrant Name",
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://www.adverum.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Tax Identification Number",
        "label": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://www.adverum.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Local Phone Number",
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "PreCommencementIssuerTenderOffer",
     "presentation": [
      "http://www.adverum.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pre-commencement Issuer Tender Offer",
        "label": "Pre-commencement Issuer Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "dei_PreCommencementTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "PreCommencementTenderOffer",
     "presentation": [
      "http://www.adverum.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pre-commencement Tender Offer",
        "label": "Pre-commencement Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "Security12bTitle",
     "presentation": [
      "http://www.adverum.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Title of 12(b) Security",
        "label": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r0"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://www.adverum.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Security Exchange Name",
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_SolicitingMaterial": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "SolicitingMaterial",
     "presentation": [
      "http://www.adverum.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Soliciting Material",
        "label": "Soliciting Material",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "TradingSymbol",
     "presentation": [
      "http://www.adverum.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Trading Symbol",
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "dei_WrittenCommunications": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "WrittenCommunications",
     "presentation": [
      "http://www.adverum.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Written Communications",
        "label": "Written Communications",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r1": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r2": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r3": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r4": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14a",
   "Subsection": "12"
  },
  "r5": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r6": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "425"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>15
<FILENAME>0001628280-25-039759-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001628280-25-039759-xbrl.zip
M4$L#!!0    ( %LX#%O@12"P' \  "I?   1    861V;2TR,#(U,#@Q,BYH
M=&WM'&ESVS;V>WX%5IDVSHQ)\=!%V5;'E9VN-O$QDK/M[)<.1$(6&HID0-"2
M^NOW/9#4;1VI+<MIOR06<3R\^\!Q^M-HX),')F(>!F?O3-UX1UC@AAX/[L_>
MG7>:K=:[GQIO3O^E:;_]W/Y$+D(W&;! DJ9@5#*/#+GL$]EGY-=0?.$/E-SZ
M5/9",="T=%@SC,:"W_<EL0RKG'?+6T7=M;MNKU*UM9I;*6DEQ["T6MDK:S5F
MUSS;,ZJ]:OGXOEZI5;HEI\<TVK49=*.NUC7LLF8QL]?U/%KK5FK'7KW">F6G
M7*JQ4L\I=9GMV"7'*]&NPPQ6+E5-!;<O 6? .XCK(Y\'7\X*?2FC>K$X' [U
MH:V'XKYH.HY35*V%K"L?R;F.HZ[P55<>0#>&Y"E*08,8L:<2Z%D$C T-$#*M
M?))1S%=!LPS#+/YV]:GC]MF :CR()0U<EH_RV'24 ALS5[\/'XK0@$#*6<?'
M$4&4IXBLQL,R3'L&F1F\-8 W-R:'OPYULZP9-<TV\WF6*#T#V+"+V-RE\01G
M;.5K^L_1J.Y3D-<""[3/G4+CM,^HUS@=,$D)CM?8UX0_G!6:82!!=K6[<03#
MW/3764&RD2PJ A4;;]Z\.95<^JQ!O8>!AK0U:J9U6DP_GA;3J;NA-VZ<>OR!
MQ'+LL[."Q^/(I^-Z$ 8,%L!'=>S(1/HG]SP6J#^A_1H42' WA3^2;=8[*[@:
MD"F@ YR)\?HYJ)B':O;!I_<%DE+UK "<J/?XB'E:C_I(*>Z=%7J:918:ZL-I
M<0["#@ O \!OW 2(@OJMP&.CCVP\F=\J- P0T+)A5LN5)2#%>0P%ZS$!)H3%
M*QB#3*['2LAA&43I5UT".\X*,1]$/G)3?>L+7.4<#_11[ &'%+PID QF'"9"
M_5)B4\]050@@JOEWIO#,?W$/?_<X$T2MB:V4\6;KXSS^BX,;^:?YV2,@3^CE
MOT!8A;P D]E ?% S4*H6VR;+]![IFK?DOW,@Q3F\<R)-J%*<$<@BB&TJNT@=
MOLEB_H[4FX[)Y'W  ZW/T*S7RZ5(G@RY)_MUTS!^**A^C=,XHB 078$<2_].
M)YE,U3B5M.NS?,9N*&!YFAOZ/HUB5L__.,E5*[4UFAIT,J#B'I;0#:4,!_4R
MK !\F.0N]37J\_N@CF3(FJ>+TXUT@1+((+T<<M:L0U-Q^;M3TQUC=9.AF^I[
M4<TG\L:,+G8D"VH,8(($."O8A05DL^6;D21QZ'./O(4%GF2-,HP66R+JH6.N
M&P0:)I"+BB0KF*1HD)+#!=EDHI"R)6^'A86BCC/CY#V0'3 L ^Z/Z^_N^  4
M^)H-23L<T.#=<0R"UDO[Q/Q/5C<K0'/U<YBB6X4I%(,R]$T+2?WYNG5W>4$Z
M=^=WEYUY03BLA78NFY_;K;O698><7U^0R]^:_SZ__N62-&^NKEJ=3NOF^F56
M;VVU^E]IW ?!D&&0KW++!9P+3GT "[Y;VPB[M!+V\8X@GPIG<J$W=0@JRR5G
M)];LU^J4++UDUP[?Z.QH6N8IX0 ELB]HM?#G :CTAYOV%=D^!LI3FS0Z3$,?
M\'TU[>-RR/./N.U'W!X/(_9E?\VM1 U\1_OR^HZT+V]OVG>'O-+;1,0)A01>
MAJ3#7,S5B&F34!"S?.2]?W3I\[*H3/0!8!/V5.T!$$D$EQSFO!RY?4@Y&#EW
M)8%F$^+90^;'[O;I5H7\EVDB,)\<>O!%&\ 4?1RF>72LC1D5&@LFN5RA<9[<
M)[$DIG6L*C)_R;CMF5B(,3*US:)02'*4_P8<?6"^).P!:U-"-;,UTGP AMK0
MR[7*01CJ \HJ+..)E28M;+39/8^Q0"6OH277!1MTP0-&)0/R,P\E<_L!+/T>
M!.F8M )7/PS-V(XB1Y<C"@8/$4>%$!.$"8U)'#$7*Q4>X0'A,B9@(D$_Q$'K
MQ_<5R&P2E6\(<?;+#Z>B6\[.]LJV=,NVU_+CI:8J;2,EFTRF%8V0[\NAT")!
M4UH^H5VH;3(+QK<82C![H0#GJ6KX'0GNM1DF@13C9NC-QQJX)8"%2\DB$3[@
M/-,@HP2>FOET2,5R23J7<.G]W6C[@?L,.G=!>3,ZE;&N;&IVI5QU_B'4A%!W
M=-3*BNNN$L1YJE4*#<O0RE:Y9EO5M63[3I3X2"DBIF@A)#N"_ &Y3NQQE;LI
MMP$.G\\J[OOO2'B.FN%@P.,XQQ6UB*0"\5VAV=+;>D<GEX/(#\=,*%SGM8!<
MA_K[9?E^F>K_\\3IYYXG6!QG_WV"^<Q<ZZN%!E"*-*D ?E*?_$K'KRD^_T9*
M-.'/&W$7#B>^M59HM)DW#$./8.,B#8YW*'C.05(VYD;<@C/G:E<]!><4&LWS
M12#?"N,VA(#!_Q^/TF@B*[$:A893,BKVUNQ<KCT? (./,APQ^XH$D)!'(*5L
MQ-Q$\@=,RD"/,;.$)C]!FT3^Y!&0SF.[I6'[QFM[7J,\G@M&Y[AK%AJ5LK'(
MV_<[B-"G$*SS;3\,%J(GT\*I*YIC6]O+SB%0=%J-^/%MS3*K)S&1S&<1HD@"
MA>.LF$ 43;]13C9DE3-;-I7#T*+KXOE!L^X#)$ 0@:5E%J'R(?A)4]4'IO5(
M6GV&K!*M*/%IG)<C]7^J+<]1C9Q'MJ(F?C:I6+T!WNPS]XO:AZ 1),-@_3%<
M[X8CTF5^.$2IP$:4'5+3/I(>]U&O>0Q*+EG@@;3($ 1FD/B2!BQ,8G],8HCY
MXMY8C<P&A%W@G@H%E9?!EIDZ7P(3@2@&X[RM!T(2#G$@9N@<(^BXOJ53M5^"
MCMN[A%\%ET Y3 V2( N/XXWGY$R[T/CQK5,ME4X6_<6/;\V*<;+\;P8(UC(+
MB40SFVCM!/2T9)4S!BQL1^$NU)%9)<T/;6+9A@X=M]UC.W >=$*?NX!D<'\%
MXH['2#8SH+0S Z90R" #LTQ]LT25)S5/3&N&#7-;@1,FE, TS?3_3KAQ*QAJ
M QZ)5&<8T*R(FUX/PZ5-7"GOS!6 IKDSX#;JAUGR,HI;1]WWV_%H=L2V7')>
M%9=:<9PPL1.O*GO@E<TRRI>.W.UX-3=BF5=[Y\B, 4X])!/@9*-51Q^4/&8>
M$_!:=I"OY)@J^):R7=YI>^3Q[R6S^C0;+27==G;;L]G#HI!2M;_#[L\=WEE(
MST>X?>)",A+O4#*=!."OG B"XCI5)MP9#[JA?Q3O4CG^3LAPG9T,4*+ ,DN>
M[AX$9-CG\'5J*G?91=E\6OW02;-#S)OZE;%I=95N3=QR%;) <*M RHX,W2]_
M83-O@[C]G:B=:6ZJM!-2UPJ-\XO_7AT8B7W66_+M$P+OJ8CU7-*>QWWIV:G%
M,P!H2^:W_TT'S4WLT:]+&P=-&G$)*=P5%5^87+@8]/B6UMX#R%;@88#,2'=,
M7%7>@4CN"]A)IG9@%THO/":P.HBN,=B[)_<B',H^QMD1EF-H3#S6 Q#J^%5:
M+C#*9/GHZO3$JDV.,'BOGJ0U@[PW5R>W(CRYA=7'-%JWNIJU8K)5YV"GLV+0
M/ATX,Z^^9:*U4"]6%WSWGWE=/D+RG3>H\HE^4?,TTVDV7[PT'LW&7CX':O76
M""7N+ZR4<+Y45^R#_#(?TB60WR!4R5,2,]4+2)J5+_'N+U<)57HA$2FG8/EC
M!*XNB2-C D +6@1[X#&, ZV@@8LU'>JZ>- (.^.U7H\*+T[KEMYCF9M]1">9
MVZRTZX1,F++U8?;M-DQF;SQ&88IQ73"?XA;?TAW(J4-18(SI$-H%KY+(Y2&;
MKDWN>G>S.KF[V1=3-WC/M*Y@](M&>Z#S=>H/Z3A&A[CZ@F?5^K8+G@M^5T,?
M63=KN>4 "00/6-?PR_YOS+4D&Q!+-ZS'ZB9K;K59IE6VG.=95YO%B2]5@?\&
M="DKTH!&D \396F&H+S8L-%:JR#&6J"X_>@NR=,@MMH>W03DR2\*'N85"SN_
M8Y$*TJ:+%GOFPS%9>^@=@IDX 9-+P?KB<0:P;HR"O:=!  ;:51M7()Y3RRTR
M@46+CZ;X:Z+.EI/4,_PG"1BQC90"QTJ.4ZNN=K9)?FB-D21"RNKD'+Y%:@\K
M3B GG5\$!"J]1 0\[L/4$(BQU+%@M-/G72Z)X^BF J(VUR:SIYTA^@)G-WDZ
MX#4ISQT0E@>3US4PD%1A6[JU/'M:(/7+*340:1D>D[A/?5\Y[RZ#6!1B H]@
MP=8"A>,^4X5VRSQ1+ 17"VZ**0,T<;6U+0/,8^0%'2C6'T\.+ [!UP,WNW_
M=.C!<2*?TR[WTYG4W!0RK0P<C,L@Q\1,V6E:X.R/K/?KH^99\#I9I!GJ/<W#
M\!GJI?(2I!NX;A8@(2ES,LZ1;TZJ9L4)-W-#%>1DV[63EW$^X\&^F14CO GU
MIL<;(0#S5#BV5C^/)TE(VIT!@NHL@O+E"AXJDN)]V#O&2 YB*3\[F83+NV<!
M^!5__L@HP7<Z$H@,D!)*\U(L5BC)EJ]&&*N>C<",40-M$M25]3@9@*:-9V\.
MOV LX.B&^5@L,'6]ZI@<NHB<C4I$XFW3IFIZ\.$U;"B8AFY5UY?)MZZXZY95
M>9*9:K9N.NNG^O;:_=H:SOY$4K$J=VC7H;Z76O4AX7[!8E?P2!UO7U&(WN$L
MT0XOJ3QSR7#^--,3;BT-N ?6_3F9M!21*"9AI/5BDCE!>EUAI==[<LS-\@_I
MTCSF9HZSKO;'L1<LAZ[T<UD<<?*2:R/I@UK94AS'_+UF6E99A=<JNM;[$E3]
M5H7;[2S<]E20LW!?_'@V%5B?2CQ7DG!:I(LUA^>X[O-2JF4:I9?7K/WA#(*;
M)CAN"(LA6)Z:E*6S"!UKD%W&@BP3EVD,WU*!$<'7!_5E1_'HB='9JM:K*.+A
MN<67K^+M^P&0[4+W3NN7Z_.[S^TUCXL]MO"-"?TSR?O2,RQIP?UKPD6666R;
M;&.G]GREWDO\,7%I@M7U60T",)"\QL J: C35P"Z#!+;'F:<.)'R%5D'3!X3
M3&?5=#21_5  <MXAISE.3;>=ZJY93JFJF\;39#EEO62NOU2^]:)*NKDA]=K2
MUZUT#I77EA!L>*5C8XI@EG>Y;_"TW9XI'7W:'<7MXA(LAM>?OXB_&OB^B_BE
MW8KX,V'H*\F]5Y/YYW%]A]CSP)$IQD7RB28"3SU_X/C$K_B6]P'V52,X<&HN
M4/*87.D7.E&A(Z:-ZCUDE;LU^YSU(&3)K[[>J*NO*TA_Z"%Z,7WF6[T-WO@_
M4$L#!!0    ( %LX#%OAUG^J70(  /8&   1    861V;2TR,#(U,#@Q,BYX
M<V3-5,ENVS 0O?LK6)U+K;$C&[$#-$&  NZ"-$%S*RAR9!.12)6D;.?O2]$B
M'"5Q"O=4G<B9]V;C&UU<[NH*;4!I+L4\2,(X0""H9%RLYL']W0W.@\O%:'3Q
M >.'3[=+="UI6X,PZ$H!,<#0EILU,FM /Z5ZY!N"OE?$E%+5&"\<[4HV3XJO
MU@:E<3KV,.]5,YH5M)R<9SBGDS-\-HU3G(_9&.>0Y2QC\7EY/OZXFDWR27$V
M+0&3(@,+(Q07<3;&*21EP1C)BTGN@N[T3-,UU 39UH2>[?0\6!O3S*)HN]V&
MVRR4:A6E<9Q$#U^6/QPTZ+$5%X\#]*Y0E<=G4><NB 8/)VQ3#^#6 *JM0RKK
MJ.LVSI,T0,08Q8O6P(T=RS64I*W,/&C%[Y94O.3 [,PKZ*8Z #QS&Z)68+Z2
M&G1#*/P]YV*$4#<)7C=2&23>9 Z;XT(;(JAM;C^^I:3$.%4<I70W['FX,^$D
MQ5D2[C0+HG^HX3#@TVKPO--K<,$TT' E-Q$#[D;X=GI]#-X=<'<8YB1"2./X
MG:6W-0T7I=P;K*DK?.:KOX72:_:5$'O9)M/I-')>JT%')HHJ6<'[X*A1L@%E
M..CG(G8!U@K*>=!)&7OY_&H4A+82#WF58/@$G=MF &T5[/I='AKR(<Q38T-H
M^PX5[$?T/_=?D>+4_BT%JA,;[XAWUH\XFP=7TNYQ@#K;_>WGHRONDNVQ/I@/
MQZ#D@CO!Q>Y+$#[\L#%RK(OH)?9%E%8#^R86[OSR47MR#WF'2$E%V^ITWJ&L
MH[3>Z&?7[U8T7*[]_=D".L-^JQ>C/U!+ P04    " !;. Q;??F!P_D)  !]
M5   %0   &%D=FTM,C R-3 X,3)?;&%B+GAM;,6<76_;.!:&[_LKM-Z;76!8
MDQ0I446;03?3#HK-M$&38@:[6!C\4B+4M@)9:9)_OZ1L)U(LRR(5JS>)8]/G
M/>\Q'YTCQ_+;7^\7\^"'+E99OGPW0:_A)-!+F:ML>?5N\NWR(V"37T]>O7K[
M-P#^^M?7L^"W7-XN]+(,3@O-2ZV"NZR\#LIK'?R9%]^S'SPXG_,RS8L% "?5
MTT[SFX<BN[HN PPQW2[;/EJ\D:&0:12'@,F( )) #!A5%# =,A4J&*<Q_>7J
M3<0B09)4 RY";99Q"00,*< :I4(ISD3$JJ#S;/G]C?TA^$H'QMYR5?WY;G)=
MEC=OIM.[N[O7]Z*8O\Z+JRF&,)QN5T\VR^]WUM^%U6J4),FT>O1QZ2IK6VC"
MHNE??YQ=R&N]X"!;KDJ^E%9@E;U957>>Y9*75=4/YA7L76'_ MMEP-X%$ 8A
M>GV_4I.35T&P+D>1S_57G0;V][>OG_9*)E.[8KK45_:U/==%EJN+DA?E&1=Z
M;K*OHI4/-_K=9)4M;N9Z>]]UH=/VL/.B:$2U628V2Q39+/^^3VPZ(/T7RK?<
MS?4%DJOL?GZI'+MJ^OG%TKTT1PA]_(1K,H-37F^H#TLUUMY]E!J<^O$S?JEM
MD9=\/L*V>)*II3RW=YR96QL9&ZCC8%KI; [=M53U?:F72J^/EHW00:;>3<RM
MF=+9["*?9S(K35O\PV149'P^@PFF&G$&)!(($"X9$)IA( 6#(H)8,!'.RL<=
M/=-+\.UB*UXI=(6?.+@J]]!9Z%5^6\AU7S.2MJ>OLSAY$@RVBF^G3YDY%V-^
M9(OSH[G+92/JW+;EO'AN(I<'3#QM\I5Q43E8:?GZ*O\Q-4^<VMG'W@#V1K6W
M]X2;[I3^?;'-D!?R0*TV*Z8R-]/&30D:94N+?-''2IGW>=76Y3*"DR OE"[,
M]-B2?&/?_%EDI:'M-%\L;I?9>OQ9S014!,$P E$JJ.7(S'B$8C/>B3"-=2)C
MV)NC5H4CH[31#)JB_6EJK\IAH 9[=6/*T:835IU6O,AJCS@:7)V&ZGQU+W1'
MS)Y5S,^O\Z7^?+L0NIA1%)N3*\*!P"H%)(812!06Y@?G.A(TA13WI>MY\".#
M5<D%E5ZP%NP/U4X=#O,TQ)T;2@[&G##:Y\"+H)U@H\&SST:=F[UKW)$YS7_H
MXKU8E06798]]TEA_O$U2R03_W0K][V6V2&OR7ONC&6FTS=%JH+XSVA>X;XOM
M.UV/)W>_F0%HAF,E6!(+@#2- ,$) 0(A 2A.E"(Q8R%3?0^GK0I'/J8^OG^W
M%@V,:F!E^Q]9V^MR&)O!;MWP<3;JA%&G&2^<VB..AE6GH3I>W0O=,3LOM!U^
MM,G0AKVT)^/%ES0U+1N'$%&")8A0&@.24@$XC!2(18PE3SF)TK@O:_MEC@R<
M$0:RIARLI8-*NS]U'64ZC-[+F'?CS\^W$X2';7F1V!%V-!P/6ZLSV6.U.YCO
M32AEPWV<\ZL9U$RH5 IS?LX30!*4@D2'*4!"$QA2#:,PZ<MB(_*1\7O4"JQ8
M?]Z:[@\CYNW)C:J>=IPP:DW=BYQFI-%@:350YZ-]@3L2'Y9E5CZ<FD %GW\R
MD-W_6S_,<$H5)BH&$,=F) PC#CB+*=!4IC)D3#,M^Z+1JG!D1-::P48TJ%0#
M(]L?EO:Z'(9FL%LW>)R-.F'4:<8+I_:(HV'5::B.5_?"P2/AI]7J5A?UB8<F
M+$H)92"!BIN.A! 0VIR)40Y%& F(,8*>@^&.V-CCX3J!EYD2=ROG/"L.JL?
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M[4+C],J-=JT;;/5=.^2><O5MC<.+X-43/?Q[=,)N<P-:X)[ (_>^;GN[3>_
M^H' GN>KDL__D]U4HUFJ%$LUXB#5H7WG$D' !!,@A9(J'>I(4^V%:T-F9%C7
MVH$1]QIF6POE"*JW_6&8]G7N#VFKL>&(-L/^'$!;K>W%LWWU0#A/S<TOQ65^
MMYPA"@F$W* 8B<0T4IP"1K &A& F$(,1D7YD/FF,C*45MBW$2GLR6:N/(Y!^
MKH?1V,NP/XJ[EH9S6(OY<R#<-;67P):E _';_#K+EAK-(@I9;$\)X]!>L9?$
MIC6F6@,84:6P0-",TEX UE5&1G!S([#:P9>E;VMLU,D11%_WPU#L;=P?QS9C
MPX%L1/TY2+89VPMEZV+_BV@OS5-GFM(HA&8^U02FIA6F"6"(**!2SJ6.D> A
M<;UVU@8^,GR/5Y):+??K9"OKA^'R->3&4S\O7I?"UA,?= 5L%6CT"U_KZ;==
M[]IXW.-+!BQ:A>;520B+0P(Q@T J^Y6'@D,@4*@!8C*E&F%,5.]W*>N!CPQ"
M-0=9+<?3L8;WPR3X.G(CH:<9MR]7:,G<[[L5ZH'&^VJ%EO0;WZS0]O@^%.H5
M-5WD^\FK[3W9^MLJ3U[]'U!+ P04    " !;. Q;IHD):ZP&  #<,   %0
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M_<WLF7@7<.#DX.%$^]&^#']R\']02P,$%     @ 6S@,6Z6TENWQ&@  */
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MR]NVT(;2MFLJ?1Q/44+13.J;>A]FVU:N\F45!"@307$8CF6,(G1D87.U*E"
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M"B(;#;.EBURR4A\D8&%P8+KZM?&YP!C6_.(83;^Z$5Y?7:GMA8'"H&Q$=<1
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M_A=02P$"% ,4    " !;. Q;X$4@L!P/   J7P  $0              @ $
M    861V;2TR,#(U,#@Q,BYH=&U02P$"% ,4    " !;. Q;X=9_JET"  #V
M!@  $0              @ %+#P  861V;2TR,#(U,#@Q,BYX<V102P$"% ,4
M    " !;. Q;??F!P_D)  !]5   %0              @ '7$0  861V;2TR
M,#(U,#@Q,E]L86(N>&UL4$L! A0#%     @ 6S@,6Z:)"6NL!@  W#   !4
M             ( ! QP  &%D=FTM,C R-3 X,3)?<')E+GAM;%!+ 0(4 Q0
M   ( %LX#%NEM);M\1H  "CP   >              "  >(B  !E>&AI8FET
M.3DQ7S@Q,C(U<')E<W-R96QE82YH=&U02P4&      4 !0!0 0  #SX

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>advm-20250812_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2025"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="advm-20250812.xsd" xlink:type="simple"/>
    <context id="c-1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501756</identifier>
        </entity>
        <period>
            <startDate>2025-08-12</startDate>
            <endDate>2025-08-12</endDate>
        </period>
    </context>
    <dei:AmendmentFlag contextRef="c-1" id="f-21">false</dei:AmendmentFlag>
    <dei:EntityCentralIndexKey contextRef="c-1" id="f-22">0001501756</dei:EntityCentralIndexKey>
    <dei:DocumentType contextRef="c-1" id="f-1">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate contextRef="c-1" id="f-2">2025-08-12</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName contextRef="c-1" id="f-3">Adverum Biotechnologies, Inc.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="c-1" id="f-4">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber contextRef="c-1" id="f-5">001-36579</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber contextRef="c-1" id="f-6">20-5258327</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="c-1" id="f-7">100 Cardinal Way</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown contextRef="c-1" id="f-8">Redwood City</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="c-1" id="f-9">CA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="c-1" id="f-10">94063</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="c-1" id="f-11">650</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="c-1" id="f-12">656-9323</dei:LocalPhoneNumber>
    <dei:WrittenCommunications contextRef="c-1" id="f-13">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial contextRef="c-1" id="f-14">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer contextRef="c-1" id="f-15">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer contextRef="c-1" id="f-16">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle contextRef="c-1" id="f-17">Common Stock</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="c-1" id="f-18">ADVM</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="c-1" id="f-19">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany contextRef="c-1" id="f-20">false</dei:EntityEmergingGrowthCompany>
    <dei:DocumentPeriodEndDate contextRef="c-1" id="f-23">2025-08-12</dei:DocumentPeriodEndDate>
    <dei:DocumentPeriodEndDate contextRef="c-1" id="f-24">2025-08-12</dei:DocumentPeriodEndDate>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
